Investment Analysts’ Weekly Ratings Changes for Sarepta Therapeutics (SRPT)

A number of research firms have changed their ratings and price targets for Sarepta Therapeutics (NASDAQ: SRPT):

  • 5/16/2019 – Sarepta Therapeutics had its price target lowered by analysts at Citigroup Inc from $201.00 to $190.00. They now have a “buy” rating on the stock.
  • 5/14/2019 – Sarepta Therapeutics had its price target lowered by analysts at Morgan Stanley from $169.00 to $165.00. They now have an “overweight” rating on the stock.
  • 5/9/2019 – Sarepta Therapeutics was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 5/9/2019 – Sarepta Therapeutics had its price target lowered by analysts at Royal Bank of Canada from $191.00 to $188.00. They now have an “outperform” rating on the stock.
  • 5/8/2019 – Sarepta Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $130.00 price target on the stock. According to Zacks, “Sarepta's Exondys 51 has witnessed impressive growth in 2018. Sarepta is also focused on reimbursement programs for better accessibility of the drug. Moreover, a potential approval to golodirsen will boost the company’s prospect as it will increase eligible patient population. Sarepta’s continues to progress with its DMD pipeline. The company is collaborating with companies and academic institutions to boost its DMD pipeline. However, dependence on a single product, Exondys 51, remains a concern. Meanwhile in December 2018, the company received a setback as it failed to gain approval for Exondys 51 in the EU. The DMD market is getting competitive as several other companies are developing therapies. The company’s shares have underperformed the industry so far this year. Loss estimates have narrowed ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in the recent quarters.”
  • 5/1/2019 – Sarepta Therapeutics was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 4/25/2019 – Sarepta Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 4/17/2019 – Sarepta Therapeutics was given a new $190.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
  • 4/11/2019 – Sarepta Therapeutics is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $175.00 price target on the stock.
  • 3/31/2019 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $213.00 price target on the stock.
  • 3/28/2019 – Sarepta Therapeutics had its price target raised by analysts at Piper Jaffray Companies from $200.00 to $208.00. They now have an “overweight” rating on the stock.

Shares of NASDAQ SRPT opened at $121.19 on Wednesday. Sarepta Therapeutics Inc has a 12 month low of $86.55 and a 12 month high of $176.50. The firm has a market cap of $8.81 billion, a PE ratio of -22.20 and a beta of 1.98. The company has a debt-to-equity ratio of 0.35, a current ratio of 12.17 and a quick ratio of 11.15.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.07) EPS for the quarter, beating the consensus estimate of ($2.05) by $0.98. Sarepta Therapeutics had a negative return on equity of 36.26% and a negative net margin of 124.66%. The business had revenue of $87.01 million during the quarter, compared to the consensus estimate of $86.92 million. On average, research analysts anticipate that Sarepta Therapeutics Inc will post -4.33 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of SRPT. TIAA CREF Investment Management LLC raised its stake in shares of Sarepta Therapeutics by 35.5% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 281,890 shares of the biotechnology company’s stock valued at $45,528,000 after acquiring an additional 73,792 shares in the last quarter. Vanguard Group Inc grew its holdings in Sarepta Therapeutics by 3.3% in the 3rd quarter. Vanguard Group Inc now owns 5,384,899 shares of the biotechnology company’s stock valued at $869,715,000 after buying an additional 170,999 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in Sarepta Therapeutics by 6.5% in the 4th quarter. State of Alaska Department of Revenue now owns 8,187 shares of the biotechnology company’s stock valued at $893,000 after buying an additional 501 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in Sarepta Therapeutics by 1,621.5% in the 4th quarter. Meeder Asset Management Inc. now owns 2,565 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 2,416 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Sarepta Therapeutics by 23.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,116 shares of the biotechnology company’s stock valued at $340,000 after buying an additional 600 shares during the last quarter. 93.01% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Read More: Why is cost of goods sold important?

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.